LncRNA PVT1 as an effective biomarker for cancer diagnosis and detection based on transcriptome data and meta-analysis

Yunhong Zeng, Tieqiang Wang, Yi Liu, Zhan Su, Pingtao Lu, Xiaoliang Chen _ and Dongsheng Hu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:75455-75466. https://doi.org/10.18632/oncotarget.20634

Metrics: PDF 1306 views  |   HTML 2444 views  |   ?  


Yunhong Zeng1,*, Tieqiang Wang2,*, Yi Liu2,*, Zhan Su2, Pingtao Lu1, Xiaoliang Chen2 and Dongsheng Hu3

1Guangming District People’s Hospital of Shenzhen, Shenzhen, Guangdong, P.R. China

2Shenzhen Guangming District Center for Disease Control and Prevention, Shenzhen, Guangdong, P.R. China

3Department of Preventive Medicine, Shenzhen University Health Science Center, Shenzhen, Guangdong, P.R. China

*These authors contributed equally to this work

Correspondence to:

Xiaoliang Chen, email: [email protected]

Dongsheng Hu, email: [email protected]

Keywords: PVT1, carcinoma, metastasis, diagnosis, meta-analysis

Received: July 26, 2017     Accepted: August 17, 2017     Published: September 04, 2017


Purpose: Long noncoding RNA (lncRNA) PVT1 was detected all types of cancer from Cancer Genome Atlas (TCGA) project; however, the role of PVT1 in cancer is not clear. This study aimed to reanalyze and determine the effect of PVT1 on cancer diagnosis, especially detection in serum.

Materials and Methods: Differential expression of PVT1 between cancers and corresponding normal tissues and receiver operating characteristic (ROC) curve were analyzed for all types of cancers in TCGA database. RevMan5.3, Meta-DiSc1.4 and STATA14.0 were used to estimate pooled diagnostic effects of PVT1 in tissue as well as serum.

Results: Compared to corresponding normal tissues, PVT1 expression was significantly upregulated in 18 types of cancer and further being an effective diagnosis biomarker in 16 of them. For the 23 diagnosis tests performed in tissue, the pooled AUC and diagnostic odd ratio (DOR) were estimated to be 0.81 (95% CI: 0.76–0.86) and 17.25 (95% CI: 8.43–35.27), when the pooled AUC and DOR were 0.83 (95%CI: 0.75–0.91) and 13.86 (95% CI: 4.70–40.66) for serum tests. Furthermore, the pooled sensitivity and specificity were 0.83 (95% CI: 0.76–0.89) and 0.74 (95% CI: 0.70–0.84) for tissue as well as 0.81 (95% CI: 0.76–0.86) and 0.76 (95% CI: 0.70–0.81) for serum.

Conclusions: PVT1, especially in serum, might be a usable biomarker for cancer diagnosis / detection.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20634